# A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

> **NCT01675973** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 4 (actual)

## Conditions studied

- Severe Renal Impairment

## Interventions

- **DRUG:** RANEXA

## Key facts

- **NCT ID:** NCT01675973
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study met stopping criteria specified within protocol.
- **Last updated:** 2012-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01675973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01675973, "A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01675973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*